Amarin is a rapidly growing, innovative pharmaceutical company focused on commercializing and developing therapeutics to cost-effectively improve cardiovascular health.

Amarin’s lead product, VASCEPA, is a prescription drug. In the United States, VASCEPA is approved and marketed by Amarin’s commercial team for two indications: one for treatment of patients with very high triglyceride levels, and one for cardiovascular risk reduction in addition to medications such as statins in high-risk patients. The latter indication is new (approved by the U.S. Food and Drug Administration in December 2019 following years of development and clinical study) and VASCEPA is the only drug approved for this use.

VASCEPA follows strict regulatory standards with a patented 3-month manufacturing process qualified to meet FDA drug standards. This process ensures the consistency and stability of VASCEPA. This is important because, if damaged, the safety and efficacy of the active ingredient can vary and is highly vulnerable to derivatives and oxidation/spoilage.